Skip to main content

Table 2 Demographic and clinical data of rheumatoid arthritis patients at entry of study

From: Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

Parameter

Respondersa

Non-responders

 

Subset 1b (n = 6)

Subset 2 (n = 10)

Subset 1 (n = 7)

Subset 2 (n = 10)

Age (years)

54.1 ± 13.8c

55.2 ± 9.2

56.1 ± 11.7

58.9 ± 11.6

Sex (men/women)

1/5

2/8

1/6

4/6

RA duration (years)

11.7 ± 8.0

11.1 ± 7.3

12 ± 10.2

10.5 ± 5.3

Methotrexate (mg/week)d

12.5 ± 5.5

13 ± 2.8

15.4 ± 2.7e

11.5 ± 3.2

Prednisone (mg/day)

12.1 ± 5.6

8.5 ± 4.2

10.3 ± 8.7

8.2 ± 5.4

Patients with NSAIDs

3

6

5

4

Patients with rheumatoid factor

4

8

5

6

Patients with anti-CCP absg

3

8

5

8

  1. aCategorised as indicated in Materials and methods. bTranscript levels were measured by microarray analysis for subset 1 or qRT-PCR for subset 2. cMean ± standard deviation. dMaximally tolerated dose in a given patient. eSignificant difference between subsets 1 and 2 within non-responders (p < 0.05, Mann and Whitney's non-parametric test). In this table, all other comparisons were non-significant. Anti-CCP abs, anti-cyclic citrullinated peptide antibodies; NSAID, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis.